GM(US:GM) Prnewswire·2025-06-22 01:35Core Insights - Innovent Biologics is showcasing multiple studies on mazdutide and IBI3030 at the American Diabetes Association's 85th Scientific Sessions, highlighting their potential in treating metabolic and cardiovascular diseases [1][2][5] Group 1: Mazdutide Developments - Mazdutide is recognized as the fastest-developing dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist globally, demonstrating significant metabolic benefits [2] - Studies indicate that mazdutide outperforms semaglutide in reducing liver fat and improving metabolic parameters, with mechanisms involving activation of oxidative phosphorylation and fatty acid degradation pathways [2][4] - Mazdutide has shown efficacy in alleviating metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis, reducing body weight, liver weight, and hepatic triglyceride levels [3][4] Group 2: IBI3030 Insights - IBI3030 is a novel anti-PCSK9 antibody-peptide conjugate that significantly improves cardiovascular risk markers by lowering plasma LDL-c levels and enhancing hepatic fatty acid oxidation [1] - Preclinical studies demonstrate that IBI3030 effectively reduces LDL-c and Lp(a), improves oral glucose tolerance, and preserves insulin sensitivity, with a maximum tolerated dose of 50 mg/kg in non-human primates [1] Group 3: Clinical Trials and Regulatory Status - Mazdutide is currently undergoing seven Phase 3 clinical studies, with several trials already meeting their primary endpoints [7][9] - The company has two New Drug Applications (NDAs) accepted for review by the National Medical Products Administration (NMPA) in China [7] Group 4: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, including oncology and metabolic disorders [9] - The company has launched 15 products and has multiple assets in clinical trials, partnering with over 30 global healthcare companies [9]